JP2009112314A5 - - Google Patents

Download PDF

Info

Publication number
JP2009112314A5
JP2009112314A5 JP2009043222A JP2009043222A JP2009112314A5 JP 2009112314 A5 JP2009112314 A5 JP 2009112314A5 JP 2009043222 A JP2009043222 A JP 2009043222A JP 2009043222 A JP2009043222 A JP 2009043222A JP 2009112314 A5 JP2009112314 A5 JP 2009112314A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administration
protein
cyclin
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009043222A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009112314A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009112314A publication Critical patent/JP2009112314A/ja
Publication of JP2009112314A5 publication Critical patent/JP2009112314A5/ja
Pending legal-status Critical Current

Links

JP2009043222A 2003-04-21 2009-02-25 疾患を処置するための方法および組成物 Pending JP2009112314A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46457103P 2003-04-21 2003-04-21

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006513191A Division JP2006524057A (ja) 2003-04-21 2004-04-21 疾患を処置するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2009112314A JP2009112314A (ja) 2009-05-28
JP2009112314A5 true JP2009112314A5 (enrdf_load_stackoverflow) 2010-03-04

Family

ID=33310915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006513191A Pending JP2006524057A (ja) 2003-04-21 2004-04-21 疾患を処置するための方法および組成物
JP2009043222A Pending JP2009112314A (ja) 2003-04-21 2009-02-25 疾患を処置するための方法および組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006513191A Pending JP2006524057A (ja) 2003-04-21 2004-04-21 疾患を処置するための方法および組成物

Country Status (7)

Country Link
US (1) US8052966B2 (enrdf_load_stackoverflow)
EP (2) EP2353389B1 (enrdf_load_stackoverflow)
JP (2) JP2006524057A (enrdf_load_stackoverflow)
AT (1) ATE513471T1 (enrdf_load_stackoverflow)
CA (1) CA2522359C (enrdf_load_stackoverflow)
ES (1) ES2366617T3 (enrdf_load_stackoverflow)
WO (1) WO2004093810A2 (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20060253262A1 (en) * 2005-04-27 2006-11-09 Emiliem Novel Methods and Devices for Evaluating Poisons
US7587843B2 (en) 2006-06-06 2009-09-15 Demers Alain P Portable ice resurfacing device and method
DE102006035617A1 (de) * 2006-07-31 2008-02-21 Siemens Ag Automatische Bestimmung von Tumorlast
PH12013500080A1 (en) * 2010-07-16 2013-03-11 Epeius Biotechnologies Corp Targeted nanoparticles for cancer and other disorders
EP2970945B1 (en) 2013-03-14 2024-05-01 GenVivo, Inc. Improved thymidine kinase gene
EP3102031B1 (en) 2014-02-05 2022-01-19 Muffin Incorporated Compartmented cryopreservation container and uses thereof
MX2016014824A (es) 2014-05-13 2017-03-23 Bioatla Llc Proteinas biologicas condicionalmente activas.
WO2020210829A1 (en) * 2019-04-12 2020-10-15 Gordon Erlinda M Methods of promoting long-term survival of patients with advanced chemotherapy-resistant malignancies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2595915A (en) * 1947-04-18 1952-05-06 Texas Co Internal-combustion engine
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
CN1038306A (zh) 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
CA2066053C (en) 1989-08-18 2001-12-11 Harry E. Gruber Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
DK0506945T3 (da) * 1990-10-25 1999-04-26 Clague Pitman Hodgson Fremgangsmåde til genoverførsel under anvendelse af retrotransposoner
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
JP3534749B2 (ja) 1991-08-20 2004-06-07 アメリカ合衆国 アデノウイルスが介在する胃腸管への遺伝子の輸送
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
EP0911413A3 (en) 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
US6239351B1 (en) 1993-07-01 2001-05-29 Hoskins Manufacturing Company Multi-wire self-diagnostic thermocouple
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
ATE189697T1 (de) 1994-03-22 2000-02-15 Immune Response Corp Inc Die hocheffiziente herstellung und isolierung von viruspartikeln
US5643770A (en) * 1994-07-21 1997-07-01 Alexion Pharmaceuticals, Inc. Retroviral vector particles expressing complement inhibitor activity
US6818439B1 (en) * 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
AU5320296A (en) 1995-03-24 1996-10-16 Genetic Therapy, Inc. Modified viral envelope polypeptide
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
US5800811A (en) 1995-06-06 1998-09-01 Hall; Frederick L. Artificial skin prepared from coclagen matrix containing transforming growth factor-β having a collagen binding site
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5980935A (en) 1996-05-15 1999-11-09 Kirpotin; Dmitri Cationic lipids and methods of use therefor
AU3597397A (en) 1996-07-09 1998-02-02 Canji, Inc. Method for measuring viral infectivity
US5962429A (en) 1996-11-22 1999-10-05 University Of Iowa Complexes of adenovirus with cationic molecules
CA2595915A1 (en) 1997-01-31 1998-08-06 Schering Corporation Methods for cultivating cells and propagating viruses
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
JP2002508765A (ja) 1997-06-23 2002-03-19 アルザ コーポレイション リポソーム被包ポリヌクレオチド組成物および方法
AU8428998A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
FR2766706B1 (fr) 1997-07-30 2001-05-25 Biovector Therapeutics Sa Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation
US20030027818A1 (en) * 2001-04-03 2003-02-06 Redmond H. Paul Treatment of cancers
EP1259605B1 (en) * 2000-03-02 2007-05-16 University of Southern California Mutated cyclin g1 protein
US7060811B2 (en) * 2000-10-13 2006-06-13 Board Of Regents, The University Of Texas System WWOX: a tumor suppressor gene mutated in multiple cancers
AU2002236517A1 (en) * 2000-11-29 2002-06-11 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CA2449087A1 (en) * 2001-08-30 2003-03-13 Tolemac, Llc Antiprotons for imaging and termination of undesirable cells
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20090123428A1 (en) * 2003-04-21 2009-05-14 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
US20070178066A1 (en) * 2003-04-21 2007-08-02 Hall Frederick L Pathotropic targeted gene delivery system for cancer and other disorders
BRPI0514068B8 (pt) * 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
CN102801264B (zh) 2012-09-04 2015-02-11 魏乐汉 永磁叠层电机

Similar Documents

Publication Publication Date Title
JP2009112314A5 (enrdf_load_stackoverflow)
CA2809900C (en) Use of interleukin-22 in treating viral hepatitis
ES2358204T3 (es) Adenovirus quiméricos para uso en el tratamiento del cáncer.
Collins et al. Viral vectors in cancer immunotherapy: which vector for which strategy?
JP7438552B2 (ja) 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
JP2010528008A5 (enrdf_load_stackoverflow)
JP2016522805A (ja) 増強された養子細胞療法
WO2004016643A3 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
JP7420751B2 (ja) I型インターフェロン及びcd40-配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
JP2017529326A5 (enrdf_load_stackoverflow)
JP2012508698A5 (enrdf_load_stackoverflow)
CN104558119B (zh) Yap蛋白抑制多肽及其应用
CN104311672B (zh) 一种具有肿瘤细胞靶向性的抑制剂多肽
JP2014515595A5 (enrdf_load_stackoverflow)
Mohr et al. Gene therapy for malignant liver disease
JP2006524057A5 (enrdf_load_stackoverflow)
CN113321736A (zh) 一种长效化白介素15融合蛋白及其制备方法和应用
JP2007511534A5 (enrdf_load_stackoverflow)
Gerspach et al. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands
Zinovieva et al. Oncolytic Vesicular Stomatitis Virus: Optimisation Strategies for Anti-Cancer Therapies
WO2007086631A1 (en) Recombinant adenoviruses capable of regulating angiogenesis
JP2007505601A5 (enrdf_load_stackoverflow)
TWI359030B (en) Treatment of cellular proliferative disorders
Tagawa et al. Cancer therapy with local oncolysis and topical cytokine secretion
CN103255170A (zh) 靶向cd47阳性白血病细胞的溶瘤腺病毒构建方法及其用途